Cue Biopharma (NASDAQ:CUE) CEO Shao-Lee Lin Sells 11,087 Shares of Stock

Posted by Francis Steltz on Oct 15th, 2026

Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) CEO Shao-Lee Lin sold 11,087 shares of the business’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $27.55, for a total value of $305,446.85. Following the completion of the sale, the chief executive officer directly owned 694,908 shares in the company, valued at $19,144,715.40. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The stock was sold at an average price of $28.62, for a total value of $522,543.96.
On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00.

Cue Biopharma Price Performance

Shares of NASDAQ:CUE opened at $18.60 on Thursday. The business has a fifty day moving average price of $27.73 and a 200-day moving average price of $72.25. The company has a market capitalization of $135.11 million, a PE ratio of -0.69 and a beta of 2.62. Cue Biopharma, Inc. has a 1-year low of $4.97 and a 1-year high of $45.50.

Cue Biopharma (NASDAQ:CUE – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%. The firm had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million. On average, sell-side analysts anticipate that Cue Biopharma, Inc. will post -21.79 earnings per share for the current fiscal year.

Institutional Trading of Cue Biopharma

A number of institutional investors have recently made changes to their positions in CUE. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Cue Biopharma during the second quarter valued at approximately $83,000. Bank of America Corp DE bought a new position in Cue Biopharma during the second quarter valued at approximately $219,000. Seven Fleet Capital Management LP bought a new position in Cue Biopharma during the second quarter valued at approximately $338,000. Persistent Asset Partners Ltd bought a new position in Cue Biopharma during the second quarter valued at approximately $389,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in Cue Biopharma in the second quarter worth approximately $722,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. B. Riley Financial began coverage on shares of Cue Biopharma in a research note on Friday, September 18th. They issued a “buy” rating and a $83.00 target price on the stock. Wall Street Zen cut shares of Cue Biopharma from a “sell” rating to a “strong sell” rating in a report on Saturday, September 26th. Weiss Ratings downgraded shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Finally, Zacks Research upgraded shares of Cue Biopharma to a “hold” rating in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cue Biopharma currently has a consensus rating of “Hold” and an average price target of $83.00.

Read Our Latest Stock Report on CUE

Cue Biopharma Company Profile

(Get Free Report)

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.